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There is strong indication that modes of ventilation
that lead to repeated closure and opening of surfactant-
deficient alveoli can induce severe functional and his-
tological lung damage [1]. New modes of ventilation
are directed at prevention of lung injury due to mechan-
ical ventilation by maintaining alveolar "gas volume" at
end-expiration, by means of positive end-expiratory pres-
sure ("gas PEEP"). Recent evidence suggests that such
modes may prevent not only lung parenchymal injury
but also proinflammatory mediator expression in the
lung tissue [2], and bacterial translocation from the lung
into the circulation [3]. The incidence of acute respira-
tory distress syndrome (ARDS) and multiple system organ
failure (MSOF), which is still the leading cause of death
in ARDS [4], may thus be reduced.
An alternative technique to maintain alveolar volume
at end-expiration is by instilling perfluorocarbon (PFC)
fluids into the lung, thereby providing "liquid PEEP" to
the alveoli. Because PFCs dissolve high amounts of oxy-
gen and carbon dioxide at normospheric pressures, gas
exchange over the alveolar air-liquid interface is main-
tained when conventional mechanical gas ventilation is
superimposed. This technique has become known as
"partial liquid ventilation" (PLV) [5].
In this issue of the European Respiratory Journal,
KAISERS et al. [6] show that mean short-term survival
time in lung-lavaged pigs treated with PLV with low
dose intratracheal PFC can be increased almost fourfold
compared to a nontreated control group, when both
groups are volume-control ventilated (tidal volume = 12
mL·kg-1; PEEP = 5 cmH2O; inspiratory/expiratory (I/E)
ratio = 1:2; fraction of inspired oxygen (FI,O2) = 1.0).
The increased survival was attributed to a preserved oxy-
gen delivery with PLV, which deteriorated in the non-
PFC-treated control group. The authors also partially
confirm previous experiences with PLV in animal mod-
els of acute lung injury (ALI), which have shown that:
1) Higher doses of PFC lead to higher levels of oxy-
genation [7]. This is suggested to result from dose-depen-
dent recruitment of collapsed atelectatic alveoli by PFC
fluid. Thereby, gas exchange also continues during the
expiratory phase of the respiratory cycle.
2) Oxygenation deteriorates over time if no additional
doses of PFC are applied [8]. This is attributed to evap-
oration of PFC, which will cause affected alveoli to col-
lapse.
3) Lung mechanics and carbon dioxide elimination
improve after an initial low dose of PFC and show no
further improvements with subsequent higher doses of
PFC [7]. This is attributed to the replacement of the
alveolar air-liquid interface with a thin air-PFC inter-
face. Evaporating PFC appears to cover the entire lung
surface. As PFCs have a low constant surface tension
(which is 12 mN·m-1 in the case of FC 3280), pulmonary
compliance is increased after a low-dose PFC and CO2
elimination is higher. No further improvement is seen
after additional PFC dosing.
4) PLV does not impair any cardiovascular parame-
ter; even in animals with a large anterior-posterior thora-
cic diameter. Mean pulmonary artery pressure decreases
when PFC is applied, due to reversal of hypoxic pul-
monary vasoconstriction [9].
5) PLV does prevent the progress of histologically
assessed lung injury [10].
6) "Gas-PEEP" has to be applied during PLV to pre-
vent bulk movement of PFC fluids from the alveoli into
the airways and to prevent dangerously high airway pres-
sures at the onset of inspiration [7].
7) PLV can be combined with other ventilatory sup-
port techniques in ALI, such as nitric oxide administra-
tion and high frequency oscillation [11, 12].
Although preliminary evaluations of phase II and III
clinical studies with PLV have shown that PFCs can be
safely applied to patients with ALI [13], these trials did
not show the tremendous improvement of gas exchange
that might have been anticipated from animal studies,
nor could they demonstrate improvement in survival of
patients treated with PLV compared to those treated with
conventional mechanical ventilation only. There is a ten-
dency towards an increased number of pneumothoraces
in patients treated with PLV. How does one explain such
findings?
Possible side-effects of PLV
There are some unclear aspects of PLV that may have
adverse consequences for the lung. Firstly, although the
alveolar air-liquid interface is eliminated when PFCs are
instilled into the alveolus, a new interface with new sur-
face tension is created at the air-PFC barrier. The law
of Laplace: P = 2γ/r, describes the relationship between
the pressure to stabilize an alveolus (P) and surface ten-
sion at the gas-liquid interface of an alveolus (γ) in rela-
tion to the radius of the alveolus (r). In the normal
"healthy" situation, surfactant present at the air-liquid
interface in the lung has the unique property of lower-
ing air-liquid surface tension in parallel with a decrease
in alveolar radius (to almost 0 mN·m-1 for low alveolar
radii), thus keeping the ratio of γ/r of the alveolus con-
stant, and guaranteeing expiratory alveolar stability at
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low pressures. PFC does not show this dynamic behaviour
of surface tension. It maintains a constant air-PFC sur-
face tension for any alveolar radius (which is 12 nN·m-1
in the case of FC 3280). 
The consequences are, firstly, that at end-expiration,
the alveolar radius is small, whereas the surface tension
is high (12 mN·m-1). Alveoli will collapse if insufficient
levels of "gas PEEP" are applied [14]. Therefore, "liq-
uid PEEP" always needs to be accompanied by a high
enough level of "gas PEEP" to prevent end-expiratory
collapse of non-PFC-filled alveoli. As KAISERS et al. [6]
point out in their discussion, insufficient PEEP levels
may subject the alveolar wall to shear forces that may
promote alveolar disruption and, successively, forma-
tion of pneumothoraces.
Secondly, concerning the level of "gas PEEP", it
depends on the disease state of the individual alveolus
whether or not the presence of a thin layer of PFC is
beneficial. In those alveoli that are unable to reduce sur-
face tension to ≤12 mN·m-1 at minimal alveolar radii,
the level of "gas PEEP" to keep alveoli open at end-
expiration will be lower during PLV than the level of
"gas PEEP" during conventional mechanical ventilation.
However, in those alveoli that still have a surfactant
system that is able to reduce surface tension to values
below 12 mN·m-1, there will be an interaction between
PFC and the normal alveolar lining fluid, leading to lev-
els of "gas PEEP" with PLV higher than those neces-
sary to keep the alveoli open with "gas PEEP" only.
Therefore, it may be important not to give PFC early
in the disease process of ALI. For the same reason, the
weaning period during the transition from PLV to nor-
mal gas breathing may be prolonged [14].
Another uncertainty with PLV is where the gas of the
tidal breaths superimposed on the PFC is going. Sug-
gesting the air would go to the non-fluid-filled parts of
the lung, there could be a severe lung overinflation in
those lung areas, due to the low surface tension of PFC,
when conventional ventilation modes, such as volume-
controlled flow constant mechanical ventilation, are used.
This may result in a high incidence of pneumothoraces
with PLV. To prevent such complications, it is manda-
tory to combine fluid PEEP with pressure-controlled
modes of ventilation, in which the pressure level in any
alveolus can never exceed the pressure level set on the
ventilator. This may prevent dangerous alveolar overdis-
tension.
Finally, there are important in vitro changes to the
cells of the immune system in the lung after exposure
to PFCs. Exposure of alveolar macrophages to PFC
decreases production of reactive oxygen metabolites
upon chemical stimulation [15]; and neutrophils exposed
to PFC produce less hydrogen peroxide (H2O2) and show
less chemotactic activity [16]. Whether such changes are
beneficial in terms of reducing lung injury due to toxic
oxygen radicals, or negative in terms of reduced host
defence against intrapulmonary pathogens, needs fur-
ther investigation.
Future considerations
Decreased oxygen delivery and increased oxygen con-
sumption with increasing levels of lactate are correlat-
ed to organ failure and mortality [17, 18]. However, it
is increasingly realized that the immune inflammatory
system plays a major role in the pathophysiology of
MSOF, and that the host's own endogenous inflamma-
tory mediators, which may be released from the lung,
contribute to organ failure and death in patients suffer-
ing from ARDS [19]. Recent preliminary data from ani-
mal studies have shown that PLV can reduce systemic
release of proinflammatory mediators in an ALI model
of acid aspiration [20]. However, the volume-controlled
ventilator settings applied to the non-PFC-treated group
in the study by KAISERS et al. [6] are not the ones cur-
rently propagated for ALI. 
Improvements in oxygen delivery and survival time
could probably also have been reached by counterbal-
ancing the increased retractive forces in the alveoli by
means of optimal ventilator settings with high end-expi-
ratory gas volumes only and small pressure amplitudes
[1]. Ventilator settings with "gas PEEP" alone have also
been shown to reduce the amount of proinflammatory
mediator expression in the surfactant-deficient lung due
to mechanical ventilation [3]. This poses the question
of whether "liquid PEEP" will have any additional value
to optimal mechanical ventilation with "gas PEEP" alone
in improving  the survival of ARDS patient. Moreover,
given the nondynamic surface tension behaviour of PFCs,
restoring the physiological situation at the alveolar air-
liquid interphase in ARDS by means of exogenous sur-
factant therapy may prove to be superior to the application
of PFCs. 
Recent studies in surfactant-depleted lungs have shown
that lung compliance can be improved to an even greater
extent if intratracheal PFC administration is preceded
by exogenous surfactant, which ensures a low interfa-
cial surface tension at low alveolar volumes [21]. Fut-
ure studies will have to demonstrate, firstly, whether
PLV or surfactant, or a combination, is the best thera-
py to overcome respiratory failure and improve patient
survival in ALI and, secondly, the impact of lung pro-
tective ventilatory strategies, such as high frequency
oscillation and pressure-controlled inverse-ratio ventila-
tion, in combination with "fluid PEEP" is superior to
the use of these strategies with surfactant or "gas PEEP"
alone. Only the ongoing phase III patient studies will
show whether or not partial liquid ventilation has an
impact on patient survival in acute lung injury.
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